{
    "hands_on_practices": [
        {
            "introduction": "Understanding the genetic underpinnings of ichthyosis vulgaris (IV) is the first step toward mastering its clinical aspects. This exercise grounds your understanding in population genetics, using the Hardy-Weinberg equilibrium principle to connect the frequency of the causative filaggrin ($FLG$) gene mutation to the observable prevalence of the disease. By incorporating the concept of incomplete penetrance, you will practice calculating how a genotype translates into a clinical phenotype at the population level, a critical skill for interpreting epidemiological data and appreciating the genetic burden of inherited skin disorders. ",
            "id": "4446845",
            "problem": "In ichthyosis vulgaris, loss-of-function variants in the filaggrin gene (FLG) produce a phenotype through impaired stratum corneum barrier formation. Consider a closed, randomly mating population at Hardy–Weinberg equilibrium (HWE), where the minor allele frequency of the FLG loss-of-function is $p=0.08$. Assume that clinically manifest disease in heterozygous carriers (one loss-of-function allele) exhibits incomplete penetrance with penetrance $f=0.6$, defined as the probability that a heterozygote expresses clinically appreciable scaling and xerosis attributable to FLG haploinsufficiency. Starting from the fundamental HWE law for genotype frequencies and the definition of penetrance as the conditional probability of phenotype given genotype, derive the expected population prevalence of clinically manifest heterozygotes as a decimal proportion and then compute its numerical value. Round your numerical answer to four significant figures. Finally, explain qualitatively, using first principles of population genetics, how deviations from HWE caused by assortative mating on skin-dryness phenotype would modify the heterozygote prevalence estimate without performing any new numerical calculation.",
            "solution": "The problem is well-posed, scientifically grounded in population genetics and medical genetics, and contains sufficient information for a unique solution.\n\nFirst, let us define the alleles and their frequencies. Let $a$ represent the loss-of-function allele of the filaggrin gene ($FLG$), and let $A$ represent the wild-type allele. The problem states that the frequency of the minor allele, which is the loss-of-function allele, is $p = 0.08$.\nThe frequency of the wild-type allele, denoted by $q$, must therefore be:\n$$q = 1 - p = 1 - 0.08 = 0.92$$\n\nThe problem specifies that the population is at Hardy–Weinberg equilibrium (HWE). According to the HWE principle, for a locus with two alleles, the genotype frequencies in the population are given by the terms of the binomial expansion of $(p+q)^2$:\n- Frequency of homozygous wild-type genotype $(AA)$: $\\text{freq}(AA) = q^2$\n- Frequency of heterozygous genotype $(Aa)$: $\\text{freq}(Aa) = 2pq$\n- Frequency of homozygous loss-of-function genotype $(aa)$: $\\text{freq}(aa) = p^2$\n\nThe problem asks for the prevalence of clinically manifest heterozygotes. This requires calculating the frequency of the heterozygous genotype $(Aa)$ and then applying the penetrance factor.\nThe frequency of heterozygous carriers in the population is:\n$$\\text{freq}(Aa) = 2pq = 2 \\times 0.08 \\times 0.92 = 0.1472$$\n\nPenetrance, $f$, is defined as the conditional probability of an individual expressing a phenotype, given that they have a particular genotype. In this case, the penetrance for heterozygotes is given as $f = 0.6$. This means that $60\\%$ of individuals with the $Aa$ genotype will exhibit clinically manifest disease.\n$$f = P(\\text{phenotype} | \\text{genotype}) = P(\\text{manifest disease} | Aa) = 0.6$$\n\nThe population prevalence of clinically manifest heterozygotes is the joint probability of an individual being heterozygous AND expressing the phenotype. This is found by multiplying the frequency of the heterozygous genotype by the penetrance of that genotype:\n$$\\text{Prevalence} = P(\\text{manifest disease and } Aa) = P(\\text{manifest disease} | Aa) \\times P(Aa)$$\n$$\\text{Prevalence} = f \\times \\text{freq}(Aa) = f \\times 2pq$$\n\nSubstituting the numerical values into this derived expression:\n$$\\text{Prevalence} = 0.6 \\times (2 \\times 0.08 \\times 0.92)$$\n$$\\text{Prevalence} = 0.6 \\times 0.1472 = 0.08832$$\n\nThe problem requires the numerical answer to be rounded to four significant figures. The calculated value is $0.08832$. The significant figures of this number are the digits starting from the first non-zero digit from the left, which are $8, 8, 3, 2$. This number thus has exactly four significant figures. Therefore, no rounding is required. The numerical value is $0.08832$.\n\nNext, we must explain qualitatively how assortative mating would modify the heterozygote prevalence estimate. Assortative mating is a form of non-random mating where individuals with similar phenotypes mate more frequently than would be expected by chance. In this context, it would mean that individuals with the \"skin-dryness phenotype\" preferentially mate with other individuals who also have dry skin.\n\nThe Hardy-Weinberg equilibrium is built upon the core assumption of random mating. Assortative mating violates this assumption. According to the first principles of population genetics, positive assortative mating (mating of like with like) leads to an increase in the proportion of homozygous genotypes ($AA$ and $aa$) and a corresponding decrease in the proportion of heterozygous genotypes ($Aa$) at the locus responsible for the phenotype, compared to the frequencies expected under HWE.\n\nThis occurs because mating becomes stratified. Matings that are most efficient at producing heterozygotes (i.e., between opposite homozygous types, $AA \\times aa$) become rarer, as these individuals are in different phenotypic pools. Matings within the affected group (e.g., $Aa \\times Aa$, $Aa \\times aa$) and within the unaffected group (e.g., $AA \\times AA$, $AA \\times Aa$) become more common. While $Aa \\times Aa$ matings produce heterozygotes, they also produce homozygotes, and the net effect across the population is a reduction in heterozygosity.\n\nTherefore, if positive assortative mating based on the skin-dryness phenotype were occurring in this population, the frequency of heterozygous individuals, $\\text{freq}(Aa)$, would be lower than the $2pq$ value calculated under the HWE assumption. Consequently, the expected population prevalence of clinically manifest heterozygotes ($f \\times \\text{freq}(Aa)$) would also be lower than our computed value of $0.08832$.",
            "answer": "$$\\boxed{0.08832}$$"
        },
        {
            "introduction": "Moving from genetics to biophysics, this practice challenges you to model the functional consequences of the filaggrin defect. You will derive an expression for transepidermal water loss (TEWL) from the fundamental principles of Fick's law of diffusion, providing a quantitative framework for the skin's barrier function. This exercise demonstrates how pathophysiological changes in IV—such as disorganized lipid lamellae, hyperkeratosis, and reduced surface humectants—can be represented by specific parameters in a physical model, allowing you to predict the magnitude of barrier impairment. ",
            "id": "4446883",
            "problem": "A researcher seeks to formalize transepidermal water loss (TEWL) in terms of fundamental transport principles and to quantify how ichthyosis vulgaris (IV) modifies its determinants. Define transepidermal water loss (TEWL) as the steady-state mass flux of water per unit area leaving the skin, and derive a closed-form expression for TEWL from Fick’s first law of diffusion, $J(x) = -D \\frac{dC}{dx}$, applied across the stratum corneum (SC) of thickness $L$ with constant diffusivity $D$ and a linear concentration profile. Use the constitutive relation $C(x) = k_{\\mathrm{sc}}\\,a(x)$, where $a(x)$ is the water activity in the SC and $k_{\\mathrm{sc}}$ is the effective solubility coefficient of water in the SC (assumed constant), and the boundary conditions $a(0)=1$ at the viable epidermis–SC interface and $a(L)=\\phi\\,h$ at the outer SC surface, where $h$ is ambient relative humidity and $\\phi$ is a dimensionless factor representing the local surface microenvironment and humectancy. Explain mechanistically how ichthyosis vulgaris (IV) alters $D$ and the boundary condition at $x=L$ through filaggrin deficiency and lipid lamellar disorganization.\n\nThen, under the following scientifically plausible parameterization, compute the ratio $R$ of IV TEWL to normal TEWL:\n- Normal skin: $D_{\\mathrm{N}} = 3.0 \\times 10^{-12}\\,\\mathrm{m^{2}\\,s^{-1}}$, $L_{\\mathrm{N}} = 2.5 \\times 10^{-5}\\,\\mathrm{m}$, $\\phi_{\\mathrm{N}} = 1.0$, $h = 0.50$, and $k_{\\mathrm{sc}} = 3.0 \\times 10^{3}\\,\\mathrm{mol\\,m^{-3}}$.\n- Ichthyosis vulgaris: $D_{\\mathrm{IV}} = \\alpha\\,D_{\\mathrm{N}}$ with $\\alpha = 2.4$ (reflecting increased permeability due to disordered lipid lamellae), $L_{\\mathrm{IV}} = \\lambda\\,L_{\\mathrm{N}}$ with $\\lambda = 1.4$ (reflecting hyperkeratosis), and $\\phi_{\\mathrm{IV}} = 0.90$ (reflecting reduced surface humectancy from decreased Natural Moisturizing Factor (NMF) production caused by filaggrin deficiency). Assume $k_{\\mathrm{sc}}$ is unchanged between normal skin and IV.\n\nLet TEWL be defined as $\\mathcal{T} = M_{w}\\,J$ where $M_{w}$ is the molar mass of water; however, for the ratio $R$ this factor cancels. Derive the analytic expression for $R$ from first principles and evaluate it numerically using the given parameters. Round your final numerical answer to four significant figures. The final answer is dimensionless, so no units are required.",
            "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, and objective. It presents a simplified but standard biophysical model of diffusion through the skin's barrier layer, the stratum corneum, based on Fick's first law. The pathophysiological changes described for ichthyosis vulgaris (IV) are consistent with established dermatological science, and the parameters provided are physically plausible. The problem is self-contained and free of contradictions, allowing for a unique solution.\n\nWe begin by deriving a general expression for transepidermal water loss (TEWL) as a steady-state mass flux. The problem defines TEWL in terms of the molar flux $J(x)$ of water, which is governed by Fick's first law in one dimension:\n$$ J(x) = -D \\frac{dC}{dx} $$\nHere, $J$ is the molar flux in units of $\\mathrm{mol\\,m^{-2}\\,s^{-1}}$, $D$ is the constant diffusivity of water in the stratum corneum (SC), and $C(x)$ is the molar concentration of water at a depth $x$ within the SC.\n\nAt steady state, the flux $J$ must be constant with respect to position $x$ to satisfy the continuity equation (mass conservation). Since $D$ is also assumed to be constant, the concentration gradient $\\frac{dC}{dx}$ must be constant as well. This confirms the problem's assumption of a linear concentration profile.\n\nWe can solve for $J$ by separating variables and integrating across the thickness of the SC, from the position $x=0$ (viable epidermis-SC interface) to $x=L$ (outer SC surface):\n$$ J \\int_{0}^{L} dx = -D \\int_{C(0)}^{C(L)} dC $$\n$$ J[x]_{0}^{L} = -D[C]_{C(0)}^{C(L)} $$\n$$ J L = -D(C(L) - C(0)) $$\n$$ J = \\frac{D}{L}(C(0) - C(L)) $$\nThis equation relates the flux to the concentration difference across the SC.\n\nNext, we use the provided constitutive relation, $C(x) = k_{\\mathrm{sc}} a(x)$, where $k_{\\mathrm{sc}}$ is the constant effective solubility coefficient of water in the SC and $a(x)$ is the water activity. We apply this at the boundaries:\n$$ C(0) = k_{\\mathrm{sc}} a(0) $$\n$$ C(L) = k_{\\mathrm{sc}} a(L) $$\nSubstituting these into the expression for $J$:\n$$ J = \\frac{D}{L}(k_{\\mathrm{sc}} a(0) - k_{\\mathrm{sc}} a(L)) = \\frac{D k_{\\mathrm{sc}}}{L}(a(0) - a(L)) $$\n\nWe now apply the given boundary conditions for water activity: $a(0)=1$ (representing full hydration at the interface with the viable epidermis) and $a(L)=\\phi h$ (where $h$ is the ambient relative humidity and $\\phi$ is a surface microenvironment factor).\n$$ J = \\frac{D k_{\\mathrm{sc}}}{L}(1 - \\phi h) $$\nThe problem defines the mass flux TEWL, denoted here as $\\mathcal{T}$, as $\\mathcal{T} = M_{w}J$, where $M_{w}$ is the molar mass of water.\n$$ \\mathcal{T} = \\frac{M_{w} D k_{\\mathrm{sc}}}{L}(1 - \\phi h) $$\nThis is the required closed-form expression for TEWL based on the model.\n\nThe problem requires a mechanistic explanation for how ichthyosis vulgaris (IV) alters the model's parameters.\nThe primary defect in IV is a deficiency of the protein filaggrin. This has two main consequences relevant to the skin barrier:\n1.  **Reduced Natural Moisturizing Factor (NMF):** Filaggrin is proteolytically processed into small, hygroscopic molecules that constitute the NMF. NMF helps retain water in the corneocytes, maintaining surface hydration. A deficiency in NMF reduces the skin's ability to bind water at its surface, decreasing its humectancy. In the model, this is captured by the parameter $\\phi$. For normal skin, $\\phi_{\\mathrm{N}} = 1.0$, implying the water activity at the surface fully equilibrates with the ambient humidity. For IV skin, NMF deficiency leads to $\\phi_{\\mathrm{IV}} < 1.0$ (given as $0.90$), reflecting lower surface water activity for the same ambient humidity. This change increases the activity gradient $(1 - \\phi h)$, which acts as the driving force for water loss.\n2.  **Disorganized Lipid Lamellae:** Filaggrin also plays a role in the proper organization of the extracellular lipid lamellae in the SC. These ordered lipids form the principal barrier to water diffusion. In IV, their disorganization creates less tortuous and more permeable pathways for water molecules. This directly increases the effective diffusivity of water through the SC. The model reflects this with an increased diffusivity, $D_{\\mathrm{IV}} > D_{\\mathrm{N}}$, quantified by the factor $\\alpha > 1$.\nAdditionally, IV is often associated with hyperkeratosis, an abnormal thickening of the SC, which is modeled as an increase in thickness, $L_{\\mathrm{IV}} > L_{\\mathrm{N}}$, quantified by the factor $\\lambda > 1$.\n\nNow, we compute the ratio $R = \\mathcal{T}_{\\mathrm{IV}} / \\mathcal{T}_{\\mathrm{N}}$. Using our derived expression for $\\mathcal{T}$:\n$$ \\mathcal{T}_{\\mathrm{N}} = \\frac{M_{w} D_{\\mathrm{N}} k_{\\mathrm{sc}}}{L_{\\mathrm{N}}}(1 - \\phi_{\\mathrm{N}} h) $$\n$$ \\mathcal{T}_{\\mathrm{IV}} = \\frac{M_{w} D_{\\mathrm{IV}} k_{\\mathrm{sc}}}{L_{\\mathrm{IV}}}(1 - \\phi_{\\mathrm{IV}} h) $$\nThe ratio $R$ is:\n$$ R = \\frac{\\mathcal{T}_{\\mathrm{IV}}}{\\mathcal{T}_{\\mathrm{N}}} = \\frac{\\frac{M_{w} D_{\\mathrm{IV}} k_{\\mathrm{sc}}}{L_{\\mathrm{IV}}}(1 - \\phi_{\\mathrm{IV}} h)}{\\frac{M_{w} D_{\\mathrm{N}} k_{\\mathrm{sc}}}{L_{\\mathrm{N}}}(1 - \\phi_{\\mathrm{N}} h)} $$\nThe terms $M_{w}$ and $k_{\\mathrm{sc}}$ cancel, as $k_{\\mathrm{sc}}$ is assumed to be unchanged.\n$$ R = \\left(\\frac{D_{\\mathrm{IV}}}{D_{\\mathrm{N}}}\\right) \\left(\\frac{L_{\\mathrm{N}}}{L_{\\mathrm{IV}}}\\right) \\left(\\frac{1 - \\phi_{\\mathrm{IV}} h}{1 - \\phi_{\\mathrm{N}} h}\\right) $$\nWe are given the relations $D_{\\mathrm{IV}} = \\alpha D_{\\mathrm{N}}$ and $L_{\\mathrm{IV}} = \\lambda L_{\\mathrm{N}}$. Substituting these:\n$$ R = \\left(\\frac{\\alpha D_{\\mathrm{N}}}{D_{\\mathrm{N}}}\\right) \\left(\\frac{L_{\\mathrm{N}}}{\\lambda L_{\\mathrm{N}}}\\right) \\left(\\frac{1 - \\phi_{\\mathrm{IV}} h}{1 - \\phi_{\\mathrm{N}} h}\\right) $$\n$$ R = \\frac{\\alpha}{\\lambda} \\left(\\frac{1 - \\phi_{\\mathrm{IV}} h}{1 - \\phi_{\\mathrm{N}} h}\\right) $$\nThis is the final analytical expression for the ratio $R$.\n\nFinally, we substitute the numerical values provided:\n$\\alpha = 2.4$\n$\\lambda = 1.4$\n$\\phi_{\\mathrm{IV}} = 0.90$\n$\\phi_{\\mathrm{N}} = 1.0$\n$h = 0.50$\n\n$$ R = \\frac{2.4}{1.4} \\left(\\frac{1 - (0.90)(0.50)}{1 - (1.0)(0.50)}\\right) $$\n$$ R = \\frac{2.4}{1.4} \\left(\\frac{1 - 0.45}{1 - 0.50}\\right) $$\n$$ R = \\frac{2.4}{1.4} \\left(\\frac{0.55}{0.50}\\right) $$\n$$ R = \\left(\\frac{2.4}{1.4}\\right) \\times 1.1 $$\n$$ R \\approx 1.7142857 \\times 1.1 $$\n$$ R \\approx 1.885714... $$\nRounding to four significant figures, the result is $1.886$.",
            "answer": "$$\\boxed{1.886}$$"
        },
        {
            "introduction": "This final practice integrates your knowledge of pathophysiology and pharmacology into a complex, realistic clinical decision-making scenario. You will conduct a quantitative risk-benefit analysis for treating an elderly IV patient with comorbidities, a task that mirrors the challenges of modern personalized medicine. By calculating drug absorption, predicting systemic concentrations, and weighing the expected therapeutic benefit against the potential for local and systemic harm, you will apply your expertise to make a reasoned, evidence-based judgment on a proposed treatment plan. ",
            "id": "4446839",
            "problem": "An elderly patient with ichthyosis vulgaris (IV) presents with diffuse scaling affecting $60\\%$ of the body surface area (BSA). The patient is aged $75$ years, weighs $70$ kilograms, and has a measured body surface area of $1.8 \\text{ m}^2$ (that is, $18,000 \\text{ cm}^2$). The patient has comorbid peripheral neuropathy, leading to reduced nociception in the distal extremities, and an estimated glomerular filtration rate (eGFR) of $45 \\text{ mL/min/1.73 m}^2$. The proposed topical regimen is high-strength salicylic acid at $12\\%$ in an ointment vehicle, applied once daily at an application thickness of $3 \\text{ mg/cm}^2$ to the $60\\%$ BSA involved ($10,800 \\text{ cm}^2$). The patient’s feet and distal legs are typically covered by socks and snug garments providing partial occlusion over $20\\%$ of total BSA (this occluded region lies entirely within the treated region), while the remaining $40\\%$ of total BSA within the treated area is non-occluded. For the purpose of risk estimation, assume that on occluded skin the fraction of applied salicylic acid absorbed systemically is $0.25$, and on non-occluded treated skin it is $0.10$.\n\nUse well-tested principles of pharmacokinetics and clinical decision analysis to estimate the benefit-to-risk balance under this regimen. For salicylate disposition at low to moderate concentrations, assume first-order elimination with volume of distribution $V_d = 0.15 \\text{ L/kg}$ and an elimination half-life $t_{1/2} = 6 \\text{ h}$ in this elderly patient. Consider that steady-state is achieved over repeated daily use and that the steady-state plasma concentration $C_{ss}$ is determined by the systemic input rate and clearance. For clinical toxicity anchoring, use the conventional mild salicylism range beginning at approximately $30 \\text{ mg/dL}$, and approximate the probability of mild salicylism at low concentrations by a first-order proportional model relative to this threshold. Locally, peripheral neuropathy is known to increase the probability of clinically significant erosions under keratolytic therapy and occlusion; assume a probability of $0.20$ for a clinically significant erosion event with a harm impact score of $50$ (on a $0$ to $100$ scale) if it occurs. If mild salicylism occurs, assign a harm impact score of $30$ (on the same scale).\n\nFor expected clinical benefit, suppose that high-strength keratolysis at $12\\%$ salicylic acid produces, across the treated area over $4$ weeks, a proportional reduction of scaling that translates to an improvement of $24$ points on an Ichthyosis Severity Score (ISS) from a baseline of $70$ (ISS is a $0$ to $100$ composite scale). Define the risk-benefit ratio as the ratio of expected benefit (ISS improvement) to expected harm (expected adverse impact score aggregated across local erosion and mild salicylism). Based on these premises, which of the following is the closest value for the risk-benefit ratio for this regimen?\n\nA. $0.50$\n\nB. $1.00$\n\nC. $2.00$\n\nD. $3.50$\n\nE. Not computable due to insufficient data",
            "solution": "The solution requires a multi-step calculation to determine the risk-benefit ratio as defined in the problem.\n\n**1. Calculate the Total Daily Systemic Dose of Salicylic Acid**\n\nFirst, we determine the amount of salicylic acid (SA) applied to the skin and then the fraction that is systemically absorbed.\n- The mass of SA applied daily to the occluded area ($A_{\\text{occluded}} = 3600 \\text{ cm}^2$): \n  $3600 \\text{ cm}^2 \\times 3 \\frac{\\text{mg}}{\\text{cm}^2} \\times 0.12 = 1296 \\text{ mg}$.\n- The mass of SA applied daily to the non-occluded area ($A_{\\text{non-occluded}} = 7200 \\text{ cm}^2$):\n  $7200 \\text{ cm}^2 \\times 3 \\frac{\\text{mg}}{\\text{cm}^2} \\times 0.12 = 2592 \\text{ mg}$.\n\nThe total amount of SA absorbed systemically per day ($D_{\\text{sys}}$) is the sum of the absorbed amounts from both regions:\n- Absorbed from occluded area: $1296 \\text{ mg} \\times 0.25 = 324 \\text{ mg}$.\n- Absorbed from non-occluded area: $2592 \\text{ mg} \\times 0.10 = 259.2 \\text{ mg}$.\n$$D_{\\text{sys}} = 324 \\text{ mg} + 259.2 \\text{ mg} = 583.2 \\text{ mg}$$\n\n**2. Calculate the Average Steady-State Plasma Concentration ($C_{\\text{ss,avg}}$)**\n\nWe use first-order pharmacokinetic principles.\n- Volume of distribution: $V_d = 0.15 \\frac{\\text{L}}{\\text{kg}} \\times 70 \\text{ kg} = 10.5 \\text{ L}$.\n- Elimination rate constant: $k_e = \\frac{\\ln(2)}{t_{1/2}} = \\frac{0.693}{6 \\text{ h}} \\approx 0.1155 \\text{ h}^{-1}$.\n- Total body clearance: $Cl = k_e \\times V_d = 0.1155 \\text{ h}^{-1} \\times 10.5 \\text{ L} \\approx 1.21275 \\text{ L/h}$.\n\nThe average steady-state concentration $C_{\\text{ss,avg}}$ is the dosing rate ($D_{\\text{sys}}/\\tau$) divided by clearance, where the dosing interval $\\tau = 24 \\text{ h}$.\n$$C_{\\text{ss,avg}} = \\frac{D_{\\text{sys}}/\\tau}{Cl} = \\frac{583.2 \\text{ mg} / 24 \\text{ h}}{1.21275 \\text{ L/h}} \\approx 20.02 \\text{ mg/L}$$\n\nConverting units to match the toxicity threshold:\n$$C_{\\text{ss,avg}} \\approx 20.02 \\frac{\\text{mg}}{\\text{L}} \\times \\frac{1 \\text{ L}}{10 \\text{ dL}} = 2.002 \\text{ mg/dL}$$\n\n**3. Calculate the Expected Harm**\n\nThe total expected harm is the sum of the expected harm from systemic salicylism and local erosion, where Expected Harm = Probability $\\times$ Harm Score.\n\n- **Expected Harm from Systemic Salicylism ($E_{H,sal}$)**:\n  - Probability of salicylism: $P_{\\text{salicylism}} = \\frac{C_{\\text{ss,avg}}}{C_{\\text{tox}}} = \\frac{2.002 \\text{ mg/dL}}{30 \\text{ mg/dL}} \\approx 0.0667$.\n  - $E_{H,sal} = P_{\\text{salicylism}} \\times H_{\\text{salicylism}} \\approx 0.0667 \\times 30 = 2.0$.\n\n- **Expected Harm from Local Erosion ($E_{H,ero}$)**:\n  - The probability is given as $P_{\\text{erosion}} = 0.20$.\n  - $E_{H,ero} = P_{\\text{erosion}} \\times H_{\\text{erosion}} = 0.20 \\times 50 = 10.0$.\n\n- **Total Expected Harm ($E_{H,total}$)**:\n  - $E_{H,total} = E_{H,sal} + E_{H,ero} = 2.0 + 10.0 = 12.0$.\n\n**4. Calculate the Risk-Benefit Ratio**\n\nThe problem defines this ratio as Expected Benefit / Expected Harm.\n- Expected Benefit: $\\Delta ISS = 24$.\n- Expected Harm: $E_{H,total} = 12.0$.\n$$ \\text{Risk-Benefit Ratio} = \\frac{\\text{Expected Benefit}}{\\text{Expected Harm}} = \\frac{24}{12.0} = 2.0 $$\n\nThe calculated risk-benefit ratio is $2.0$.\n\n**Option-by-Option Analysis**\n- **A. $0.50$**: This value is incorrect. It may result from inverting the ratio to a risk/benefit calculation ($12/24=0.5$), which contradicts the problem's explicit definition.\n- **B. $1.00$**: This value is incorrect. It would imply that the expected benefit is equal to the expected harm ($24/24=1$ or $12/12=1$), which is not supported by the calculation.\n- **C. $2.00$**: This value matches the derived result of $2.0$. The calculation shows that the expected benefit of $24$ points is twice the aggregated expected harm score of $12.0$ points. **Correct**.\n- **D. $3.50$**: This value is incorrect. There is no plausible calculation error that would lead to this result. It is significantly different from the derived value.\n- **E. Not computable due to insufficient data**: This is incorrect. The problem provides a comprehensive set of data, assumptions, and models, making the calculation entirely feasible.",
            "answer": "$$\\boxed{C}$$"
        }
    ]
}